BEGIN:VCALENDAR
PRODID:-//AT Content Types//AT Event//EN
VERSION:1.0
BEGIN:VEVENT
DTSTART:20101112T003000Z
DTEND:20101113T010000Z
DCREATED:20100615T125701Z
UID:ATEvent-cbc7ba9c5ea48e1815c44f4bbbeff347
SEQUENCE:0
LAST-MODIFIED:20100618T001131Z
SUMMARY:Allosteric Modulator Congress
DESCRIPTION:This conference will highlight the entire drug discovery p
 rocess as it pertains to the development of allosteric modulators and 
 the challenges and recent successes associated with this exciting fiel
 d.\n\nThemes include\:\n\nScreening for a specific target\, Hit to lea
 d generation\, Lead optimization to clinical candidate\, Medicinal che
 mistry and Structure Activity Relationships (SARs) of allosteric modul
 ators\, Therapeutic applications of Allosteric Modulators.\n\nBackgrou
 nd\:\n\nAllosteric modulators are an emerging class of orally availabl
 e small molecule therapeutic agents that may be able to offer patients
  better outcomes than with traditional small molecule therapies. This 
 potential stems from their ability to offer greater selectivity and be
 tter modulatory control at disease mediating receptors. Modulators bin
 d to regulatory sites distinct from the active site on the protein\, r
 esulting in conformational changes that may profoundly influence prote
 in function. The advent of functional assays as the screening method o
 f choice is leading to an increase in the number of allosteric modulat
 ors identified.\n\nAllosteric modulation is generating a great deal of
  excitement among researchers. Since orthosteric modulators need to co
 mpete with natural ligands\, they require higher doses\, raising safet
 y issues. Allosteric modulators do not compete and may be effective at
  lower\, safer doses.
PRIORITY:3
TRANSP:0
END:VEVENT
END:VCALENDAR